SRPT

$0.00

(

+0.00%

)
Quote details

stock

Sarepta Therapeutics Inc

NASDAQ | SRPT

21.71

USD

+$0.00

(

+0.00%

)

At Close (As of Dec 15, 2025)

$2.26B

Market Cap

-

P/E Ratio

-2.83

EPS

$129.84

52 Week High

$10.41

52 Week Low

HEALTHCARE

Sector

SRPT Chart

Recent Chart
Price Action

SRPT Technicals

Tags:

SRPT Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.6B
Total Revenue $1.9B
Cost Of Revenue $319M
Costof Goods And Services Sold $319M
Operating Income $218M
Selling General And Administrative $558M
Research And Development $805M
Operating Expenses $1.4B
Investment Income Net -
Net Interest Income $53M
Interest Income $72M
Interest Expense $18M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $54M
Income Before Tax $261M
Income Tax Expense $26M
Interest And Debt Expense -
Net Income From Continuing Operations $235M
Comprehensive Income Net Of Tax -
Ebit $279M
Ebitda $333M
Net Income $235M

Revenue & Profitability

SRPT Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $4B
Total Current Assets $3.1B
Cash And Cash Equivalents At Carrying Value $1.1B
Cash And Short Term Investments $1.1B
Inventory $750M
Current Net Receivables $650M
Total Non Current Assets $890M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $27M
Intangible Assets Excluding Goodwill $27M
Goodwill -
Investments -
Long Term Investments $137M
Short Term Investments $252M
Other Current Assets $319M
Other Non Current Assets -
Total Liabilities $2.4B
Total Current Liabilities $732M
Current Accounts Payable $214M
Deferred Revenue -
Current Debt -
Short Term Debt $13M
Total Non Current Liabilities $1.7B
Capital Lease Obligations $206M
Long Term Debt $1.1B
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.3B
Other Current Liabilities $356M
Other Non Current Liabilities $49M
Total Shareholder Equity $1.5B
Treasury Stock -
Retained Earnings -$4.2B
Common Stock $10K
Common Stock Shares Outstanding $108M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$206M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $38M
Capital Expenditures $137M
Change In Receivables -
Change In Inventory -$395M
Profit Loss -
Cashflow From Investment $756M
Cashflow From Financing $125M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $235M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.6B
Total Revenue $1.9B
Cost Of Revenue $319M
Costof Goods And Services Sold $319M
Operating Income $218M
Selling General And Administrative $558M
Research And Development $805M
Operating Expenses $1.4B
Investment Income Net -
Net Interest Income $53M
Interest Income $72M
Interest Expense $18M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $54M
Income Before Tax $261M
Income Tax Expense $26M
Interest And Debt Expense -
Net Income From Continuing Operations $235M
Comprehensive Income Net Of Tax -
Ebit $279M
Ebitda $333M
Net Income $235M

SRPT News

SRPT Profile

Sarepta Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Sarepta Therapeutics, Inc. is a leading biopharmaceutical company located in Cambridge, Massachusetts, specializing in RNA-targeted and gene therapies for rare genetic disorders, with a notable focus on Duchenne muscular dystrophy (DMD). The company boasts a robust pipeline of innovative therapies aimed at addressing critical unmet medical needs, positioning itself at the forefront of genetic medicine. Leveraging advanced scientific expertise and pioneering technologies, Sarepta is committed to transforming treatment paradigms and enhancing patient outcomes in the biopharmaceutical industry.

LPTX
+368.57%
$2.05
WOK
-37.59%
$0.06
MASK
+45.85%
$0.43
OCG
-18.22%
$0.17
NVDA
+0.70%
$176.25
YGMZ
-61.42%
$0.02
PAVS
-13.38%
$0.03
ASST
-7.00%
$0.80
IRBT
-71.16%
$1.24
TSLA
+3.89%
$476.82
ONDS
-9.71%
$7.90
AMCI
+156.82%
$6.96
CGC
-1.72%
$1.71
PLUG
-2.15%
$2.27
AXDX
-61.36%
$0.03
MIST
-4.97%
$2.29
YCBD
+2.91%
$1.23
AAL
+1.76%
$15.22
LAZR
-62.10%
$0.34
ASBP
+0.63%
$0.09
ADAP
-15.14%
$0.05
BITF
-8.21%
$2.51
AVGO
-5.28%
$340.89
BMNU
-17.95%
$6.81
VHAI
0.00%
$0.00
BMNR
-9.06%
$31.70
RIVN
+5.67%
$19.46
BYND
-3.66%
$1.05
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
CIFR
-13.10%
$14.81
ADD
-25.47%
$0.05
PFE
+2.66%
$26.53
INTC
-0.21%
$37.72
IREN
-10.00%
$36.11
F
-0.52%
$13.68
CLSK
-13.87%
$12.08
ARTV
+96.21%
$6.47
SRM
+53.27%
$10.30
MARA
-5.68%
$10.86
DNN
-1.53%
$2.57
ORCL
-2.38%
$185.43
APLD
-14.53%
$23.80
SOFI
-2.83%
$26.50
TWOH
-7.69%
$0.00
ACHR
-4.93%
$7.89
SNAP
+0.95%
$7.38
WULF
-12.59%
$12.52
BTBT
-7.11%
$2.09
TLRY
-6.48%
$11.36
AAPL
-1.74%
$273.42
NFLX
-1.57%
$93.69
RKLB
-9.17%
$55.85
BBD
+0.57%
$3.47
PLTR
+1.00%
$185.42
RIG
-1.33%
$4.07
KVUE
-0.40%
$17.26
BTG
+0.54%
$4.62
KIND
-14.44%
$2.37
PFSA
-16.39%
$0.12
AMZN
-1.48%
$222.82
RGTI
-7.48%
$23.90
CAN
-7.93%
$0.77
ATPC
-6.00%
$0.12
AFMD
-34.94%
$0.18
NIO
+0.39%
$5.05
IMG
+12.33%
$1.81
T
-0.58%
$24.43
WBD
-0.78%
$29.74
QBTS
-8.29%
$23.93
SOUN
-7.03%
$10.83
IVP
-3.65%
$0.04
CRWV
-6.62%
$73.38
DVLT
-5.80%
$1.29
BAC
+0.71%
$55.53
CLYM
+28.33%
$3.85
BURU
-6.21%
$0.19
RR
-13.67%
$3.55
AMC
-5.66%
$2.00
HPE
+0.79%
$24.05
FI
+0.86%
$68.75
GRAB
-1.85%
$5.05
TE
-4.29%
$5.12
VIVK
-14.30%
$0.06
GRYP
-10.38%
$1.38
AMD
-0.68%
$209.33
GOOGL
-0.55%
$307.57
MODV
-25.22%
$0.43
CHR
-6.31%
$0.03
VALE
+0.55%
$12.76
PLTD
-1.31%
$6.37
HOOD
-2.53%
$116.47
KDLY
-7.79%
$0.40
UBER
-2.87%
$82.66
KYTX
+26.57%
$11.11
MSTR
-7.25%
$163.64
IONQ
-9.21%
$45.71
AG
+1.85%
$16.23
NOK
-1.03%
$6.20
LPTX
+368.57%
$2.05
WOK
-37.59%
$0.06
MASK
+45.85%
$0.43
OCG
-18.22%
$0.17
NVDA
+0.70%
$176.25
YGMZ
-61.42%
$0.02
PAVS
-13.38%
$0.03
ASST
-7.00%
$0.80
IRBT
-71.16%
$1.24
TSLA
+3.89%
$476.82
ONDS
-9.71%
$7.90
AMCI
+156.82%
$6.96
CGC
-1.72%
$1.71
PLUG
-2.15%
$2.27
AXDX
-61.36%
$0.03
MIST
-4.97%
$2.29
YCBD
+2.91%
$1.23
AAL
+1.76%
$15.22
LAZR
-62.10%
$0.34
ASBP
+0.63%
$0.09
ADAP
-15.14%
$0.05
BITF
-8.21%
$2.51
AVGO
-5.28%
$340.89
BMNU
-17.95%
$6.81
VHAI
0.00%
$0.00
BMNR
-9.06%
$31.70
RIVN
+5.67%
$19.46
BYND
-3.66%
$1.05
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
CIFR
-13.10%
$14.81
ADD
-25.47%
$0.05
PFE
+2.66%
$26.53
INTC
-0.21%
$37.72
IREN
-10.00%
$36.11
F
-0.52%
$13.68
CLSK
-13.87%
$12.08
ARTV
+96.21%
$6.47
SRM
+53.27%
$10.30
MARA
-5.68%
$10.86
DNN
-1.53%
$2.57
ORCL
-2.38%
$185.43
APLD
-14.53%
$23.80
SOFI
-2.83%
$26.50
TWOH
-7.69%
$0.00
ACHR
-4.93%
$7.89
SNAP
+0.95%
$7.38
WULF
-12.59%
$12.52
BTBT
-7.11%
$2.09
TLRY
-6.48%
$11.36
AAPL
-1.74%
$273.42
NFLX
-1.57%
$93.69
RKLB
-9.17%
$55.85
BBD
+0.57%
$3.47
PLTR
+1.00%
$185.42
RIG
-1.33%
$4.07
KVUE
-0.40%
$17.26
BTG
+0.54%
$4.62
KIND
-14.44%
$2.37
PFSA
-16.39%
$0.12
AMZN
-1.48%
$222.82
RGTI
-7.48%
$23.90
CAN
-7.93%
$0.77
ATPC
-6.00%
$0.12
AFMD
-34.94%
$0.18
NIO
+0.39%
$5.05
IMG
+12.33%
$1.81
T
-0.58%
$24.43
WBD
-0.78%
$29.74
QBTS
-8.29%
$23.93
SOUN
-7.03%
$10.83
IVP
-3.65%
$0.04
CRWV
-6.62%
$73.38
DVLT
-5.80%
$1.29
BAC
+0.71%
$55.53
CLYM
+28.33%
$3.85
BURU
-6.21%
$0.19
RR
-13.67%
$3.55
AMC
-5.66%
$2.00
HPE
+0.79%
$24.05
FI
+0.86%
$68.75
GRAB
-1.85%
$5.05
TE
-4.29%
$5.12
VIVK
-14.30%
$0.06
GRYP
-10.38%
$1.38
AMD
-0.68%
$209.33
GOOGL
-0.55%
$307.57
MODV
-25.22%
$0.43
CHR
-6.31%
$0.03
VALE
+0.55%
$12.76
PLTD
-1.31%
$6.37
HOOD
-2.53%
$116.47
KDLY
-7.79%
$0.40
UBER
-2.87%
$82.66
KYTX
+26.57%
$11.11
MSTR
-7.25%
$163.64
IONQ
-9.21%
$45.71
AG
+1.85%
$16.23
NOK
-1.03%
$6.20

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.